nature portfolio

Corresponding author(s):	Manuela De Michele
Last updated by author(s):	Jul 8, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics			
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a Confirmed			
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
A description of all covariates tested			
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated			
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
Software and code			
Policy information about <u>availability of computer code</u>			
Data collection No software was used for Data collection			
Data analysis No software was used for Data analysis			
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.			
Data			

Policy information about $\underline{availability}$ of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data of this report are available from the corresponding author upon reasonable request

Field-spe	cific re	porting		
Please select the or Life sciences		the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Chavioural & social sciences		
For a reference copy of t	he document with a	Il sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Lite scier	ices stu	ıdy design		
All studies must disclose on these points even when the disclosure is negative.				
Sample size	No sample size o	size calculation was perfomed as this study consists of two case reports		
Data exclusions	No Data were ex	ata were excluded		
Replication	Not applicable to this study			
Randomization	Randomization i	domization is not applicable to this study, since it consists of two case reports		
Blinding	authors who per	authors who performed laboratory and histological analysis were blinded on clinical Data of patients		
Reporting for specific materials, systems and methods We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Materials & experimental systems Methods				
Antibodies				
Antibodies used	Antiboo	dies to platelet factor 4 (PF4)/polyanion IgG/IgA/IgM Immucor, Lifecodes, Waukesha, WI		
Validation		LIFECODES PF4 Enhanced for in vitro diagnostic use [package insert], Waukesha, WI; Immucor GTI Diagnostics, Inc., 2013 LIFECODES PF4 IgG for in vitro diagnostic use [package insert], Waukesha, WI; Immucor GTI Diagnostics, Inc., 2013		
Human resea	arch partic	cipants		
Policy information about <u>studies involving human research participants</u>				
Population charac	cteristics	In the study we have described two females between 50 and 60 years of age, with acute ischemic stroke diagnosis and without past medical history relevant for the current diagnosis.		

Healthy volunteers have been randomly recruited as healthy platelets and serum donors according to Italian regulation

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Institutional review board at Sapienza University of Rome

Recruitment

Ethics oversight

Magnetic resonance in	naging	
Experimental design		
Design type	N/A	
Design specifications	N/A	
Behavioral performance measure	es N/A	
Acquisition		
Imaging type(s)	structural, diffusion, perfusion	
Field strength	1.5 Tesla	
Sequence & imaging parameters	1) Diffusion-Weighted Imaging (DWI) with b=0/1000s/mm2, 5 mm thick axial slices with corresponding apparent diffusion coefficient (ADC) mapping; 2) Fluid-Attenuated Inversion Recovery (FLAIR); 3) T1 sequences 4) T2 sequences 5) Grandient echo (GRE) sequences; 6) 3d Time-of-Flight (3D TOF) MR angiography (MRA); 7) Dynamic susceptibility contrast (DSC) MR perfusion-weighted imaging (PWI), and 8) T1 volumetric Interpolated Breath-hold Examination (VIBE) post injection of gadolinium contrast agent (on saggital plane)	
Area of acquisition	whole brain scan	
Diffusion MRI 🔀 Used	Not used	
Parameters large nu	umber of directions (>6), b value=0/1000s/mm, multi shell	
Preprocessing		
Preprocessing software	N/A	
Normalization	N/A	
Normalization template	N/A	
Noise and artifact removal	N/A	
Volume censoring	N/A	
Statistical modeling & infere	nce	
Model type and settings	N/A	
Effect(s) tested	N/A	
	hole brain ROI-based Both	
Statistic type for inference (See Eklund et al. 2016)	N/A	
Correction	N/A	
Models & analysis		
n/a Involved in the study		
Functional and/or effective connectivity		
Graph analysis Multivariate modeling or p	redictive analysis	